 |
| PRESS RELEASE >> APRIL 05 - 2007 | ||
Vancouver, British Columbia, April 5, 2007 – ProtoKinetix, Inc. (the "Company") (OTCBB: PKTX) has ascertained that the presence of AAGP™ not only protects delicate stem cells against the harsh storage environment but also prevents the premature differentiation into an undesirable cellular state. Tests have been commissioned to take place at one of Europe’s most prestigious stem cell research centres using human embryonic and neuronal stem cells. Current survival and viability of human stem cells can be as low as 5% using existing storage protocols. The addition of a small concentration of AAGP™ has, to date, yielded as high as 100% viability. Cryopreservation of stem cells is a market that has exploded in recent years. ProtoKinetix’ entry into this multi billion dollar market is just another example of the many commercial applications of this family of molecules. FOR FURTHER INFORMATION, investors are invited to visit the ProtoKinetix Investor Relations Hub at www.agoracom.com/IR/ProtoKinetix where they can post questions and receive answers or review questions and answers already posted by other investors. About ProtoKinetix ProtoKinetix Inc. is a Biotechnical Company that has researched and produced a patented family of synthetic Anti-Aging Glycoprotein (AAGP™) molecules for use in cosmetics, cryopreservation, organ transplantation and anti-inflammatory medicine. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. On behalf of the Board of Directors Dr. John Todd – President CONTACT INFORMATION Corporate Inquiries Investor Relations AGORACOM Investor Relations
|
|
|
HOME - AFGP to AAGP - AAGP TESTS - COMMERCIAL APPLICATIONS - PRESS RELEASES - CONTACT Copyright 2008 © Protokinetix Inc. All rights reserved. | Privacy Policy | Safe Harbor | |
